Faricimab for newly diagnosed wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older and have agreed to participate.
- You have been diagnosed with active wet AMD that has not been treated before.
- Your vision in the study eye is at least 20/800 (or able to read 24 letters on an eye chart).
- If you have a type of wet AMD called polypoidal choroidal vasculopathy (PCV), the active lesion in your macula must be smaller than 5.4 mm in diameter.
- You do not have other eye conditions or prior eye surgeries that could interfere with the study.
- You are not pregnant, breastfeeding, or planning pregnancy during the study and for 3 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This trial tests a new drug called Faricimab for people with a specific type of wet age-related macular degeneration (AMD) that has a buildup of material beneath the retina. The goal is to see if Faricimab can help clear this material and improve vision.
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
This study observes the effects of a drug called faricimab (given as eye injections) on people with wet age-related macular degeneration (AMD), a condition causing rapid vision loss from abnormal blood vessels leaking fluid in the back of the eye. It aims to see how well the drug works when given in a specific schedule and to monitor safety and outcomes over time. This is an observational study, so you would receive the treatment as part of your normal care, and the research team will collect data.
This trial tests a new eye drop-free injection medication called faricimab for people with wet age-related macular degeneration who haven't improved enough on standard anti-VEGF shots. The goal is to see if it can reduce fluid and improve vision better than usual treatments.
This study tests a medication called faricimab, given as eye injections over a long period, for people with a specific type of wet age-related macular degeneration. The goal is to see if this treatment can help maintain or improve vision over time.
Hear when a new Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.